I think it's safe to say the Lm platform is efficacious. Now, it's being fortified (for lack of a better word) to promote a stronger immune response. BP, I think, has to be interested. Amgen would be the obvious choice for a bigger, better partnership but I wouldn't rule out Merck. It's just a matter of time.